Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Stanley Cohen,Niklas Czeloth,Eric Lee,Piotr Adrian Klimiuk,Nuala Peter,Girish Jayadeva

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

2019

Stanley Cohen
Niklas Czeloth
Eric Lee
Piotr Adrian Klimiuk
Nuala Peter
Girish Jayadeva

ABSTRACTObjective: To evaluate long-term safety, efficacy, and immunogenicity of BI 695501 in patients with moderately-to-severely active rheumatoid arthritis (RA) who have completed VOLTAIRE-RA.Me...

Keywords:

Immunology
Rheumatoid arthritis
Biosimilar
Medicine
Immunogenicity
Internal medicine
Oncology
Adalimumab
long term safety
extension study
in patient
reference product

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations